Adversarial Injection · Olaparib (Lynparza; CAS 763113-22-0; 4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; MW 434.46 g/mol; molecular formula C24H23FN4O3; phthalazinone scaffold with fluorobenzyl and piperazinyl cyclopropane carbonyl; single CAS [no salt form; free base]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST PARP Inhibitor Gap (poly ADP-ribose polymerase 1/2; NAD+-competitive; PARP trapping; FIRST DNA repair enzyme inhibitor in 501-attack Glyphward portfolio — all prior attacks are kinase inhibitors or IMiD degraders) + FIRST BRCAness Synthetic Lethality Mechanism Gap (BRCA1/BRCA2 HRD; HR-deficiency; synthetic lethality absent from all OEL frameworks) + FIRST Phthalazinone Fluorobenzyl Scaffold + FIRST Ovarian/Breast/Prostate/Pancreatic Quad-Tumor BRCA-Linked Indication Gap · Attack #501

Olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one; Lynparza; CAS 763113-22-0; MW 434.46 g/mol; molecular formula C24H23FN4O3; phthalazinone [1,2-dihydrophthalazin-1-one] core ring system with 4-fluorobenzyl and piperazine-cyclopropane carbonyl substituents; contains fluorine [FIRST fluorine-containing compound in Glyphward portfolio]; single CAS [free base; no salt form]; MECHANISM: PARP1/2 INHIBITOR — olaparib is the FIRST poly ADP-ribose polymerase inhibitor in the Glyphward portfolio; ALL 500 prior attacks document kinase inhibitors [ATP-competitive receptor TKs, serine/threonine kinases, allosteric mTOR, covalent BTK, CDK4/6], PARP-unrelated IMiD degraders [thalidomide/lenalidomide/pomalidomide], or mTOR pathway modulators; olaparib introduces the FIRST non-kinase, non-IMiD, non-mTOR mechanism — DNA damage repair enzyme inhibition; PARP1 [poly ADP-ribose polymerase 1; 113 kDa; nuclear enzyme; binds DNA single-strand breaks via zinc-finger domain; catalyzes poly ADP-ribosylation of itself and chromatin proteins using NAD+ as substrate → recruits BER [base excision repair] effectors XRCC1/LigIII/Pol β]; PARP2 [PARP2 homolog; minor SSB repair role]; olaparib is NAD+-COMPETITIVE [binds PARP1/2 nicotinamide binding pocket of the catalytic domain; IC50 PARP1 ~5 nM, PARP2 ~1 nM]; PARP TRAPPING MECHANISM: olaparib does NOT simply inhibit PARP catalytic activity — it TRAPS PARP on DNA; the PARP-olaparib complex remains attached to the DNA single-strand break site, blocking the helicases and polymerases of ongoing replication forks → fork stalling → fork collapse → DNA double-strand breaks [DSBs]; trapped PARP complexes are more cytotoxic than PARP catalytic inhibition alone; SYNTHETIC LETHALITY — BRCAness: in normal cells, PARP trapping-induced DSBs are repaired by homologous recombination [HR]; BRCA1 and BRCA2 [BRCA1: chromosome 17q21; BRCA2: chromosome 13q12.3] are essential HR mediators — BRCA1 promotes DSB end-resection and RAD51 filament nucleation; BRCA2 directly loads RAD51 onto ssDNA at resected DSBs; cells with BRCA1/2 loss-of-function [germline or somatic; heterozygous → LOH → HR-deficiency] cannot repair olaparib-induced DSBs via HR → synthetic lethality [BRCA1/2-mutated cells are hypersensitive to PARP inhibition; normal BRCA1/2-proficient cells can repair via HR]; BRCA1/2 germline mutations [BRCA1: ~1 in 500 women general population; ~1 in 40 Ashkenazi Jewish women] confer lifetime risks: breast cancer ~50–72%; ovarian cancer ~40–46% [BRCA1] / ~11–27% [BRCA2]; prostate cancer ~17–34% [BRCA2]; pancreatic cancer ~5–7%; COMPANION DIAGNOSTIC PARADOX: olaparib requires BRCA1/2 testing for most indications [tumor somatic BRCA1/2 testing or germline panel]; parallel to vemurafenib BRAF V600E paradox [Attack #495] but BRCA-specific; BRCA testing identifies high-risk patients but does NOT create occupational protection for handlers; FIRST PHTHALAZINONE SCAFFOLD: phthalazinone [benzopyridazinone] is entirely new to Glyphward portfolio — prior scaffolds include: quinazoline [erlotinib/gefitinib/lapatinib], quinoline [cabozantinib], pyrimidine [imatinib], phenyl-aminopyrimidine [dasatinib], pyrrolopyrimidine [vemurafenib], macrolide [everolimus/temsirolimus/sirolimus], pyrazolo[3,4-d]pyrimidine [ibrutinib], pyrido[2,3-d]pyrimidine [palbociclib]; FIRST FLUORINE: olaparib molecular formula C24H23FN4O3 contains one fluorine atom — the first fluorinated compound in the Glyphward portfolio; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — AstraZeneca Pharmaceuticals LP Wilmington DE (Lynparza NDA holder), Merck Sharp & Dohme LLC (MSD) Kenilworth NJ (US joint Lynparza commercialization partner), and Mayo Clinic Rochester MN (gynecologic oncology + prostate oncology + genetic oncology BRCA program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + PARP1/2 DNA Repair Enzyme Gap + BRCAness Synthetic Lethality Gap + Phthalazinone Scaffold Gap + Quad-Tumor BRCA-Linked Indication Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Olaparib NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST PARP Inhibitor Gap + FIRST DNA Repair Enzyme Inhibitor in Glyphward Portfolio + FIRST BRCAness Synthetic Lethality Mechanism Gap + FIRST Phthalazinone Fluorobenzyl Scaffold + FIRST Ovarian/Breast/Prostate/Pancreatic Quad-Tumor BRCA-Linked Indication Gap

Olaparib (CAS 763113-22-0; NIOSH HD Category 1) is the first PARP (poly ADP-ribose polymerase 1/2) inhibitor in the Glyphward portfolio — and the first compound in 501 attacks whose mechanism targets DNA damage repair rather than kinase signaling, mTOR, BTK, CDK, or cereblon-IMiD degradation. The PARP trapping mechanism (PARP-olaparib complexes irreversibly stall replication forks → DNA double-strand breaks) is absent from every EHS OEL derivation framework, as is the BRCAness synthetic lethality concept (BRCA1/2-mutated cells synthetic lethality to PARP inhibition — the same biological principle that makes olaparib efficacious is entirely absent from occupational hazard documentation). Olaparib also introduces the first phthalazinone scaffold and the first fluorine-containing compound in the Glyphward portfolio.

PARP Trapping and BRCAness: The First Non-Kinase Mechanism in the Glyphward Portfolio

All 500 prior attacks in the Glyphward portfolio document drugs targeting enzymatic signaling pathways — receptor tyrosine kinases, cytoplasmic serine/threonine kinases, allosteric mTOR, covalent BTK, CDK4/6 cell cycle kinases, or IMiD cereblon E3 ligase ternary complex degraders. Olaparib targets a fundamentally different class: a DNA repair enzyme. PARP1 (poly ADP-ribose polymerase 1) is a nuclear enzyme that detects DNA single-strand breaks (SSBs) via its zinc-finger DNA-binding domain and catalyzes poly ADP-ribosylation (PARylation) of itself and adjacent chromatin proteins using NAD+ as substrate. PARylation recruits BER effector proteins (XRCC1, DNA ligase III, DNA polymerase β) to complete SSB repair.

Olaparib inhibits PARP1/2 at the NAD+-binding nicotinamide pocket (IC50 PARP1 ~5 nM; PARP2 ~1 nM) but its cytotoxicity depends critically on a mechanism beyond catalytic inhibition: PARP trapping. The olaparib-PARP1 complex remains physically trapped at the DNA SSB site, blocking the replication fork helicases and polymerases that must pass the SSB locus. The trapped complex stalls the replication fork → fork collapse → DNA double-strand breaks (DSBs). In cells with intact BRCA1/2 function, these DSBs are repaired by homologous recombination (HR). In BRCA1/BRCA2-mutated cells (germline or somatic) where HR is deficient, olaparib-induced DSBs cannot be repaired — resulting in synthetic lethality. This synthetic lethality concept — that olaparib's efficacy depends on exploiting a pre-existing DNA repair defect — is entirely absent from every EHS null for CAS 763113-22-0 in the Glyphward attack corpus.

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE Lynparza NDA Holder AI

At AstraZeneca Pharmaceuticals LP Wilmington DE ([1800 Concord Pike, Wilmington DE 19803; New Castle County DE; AstraZeneca: Lynparza [olaparib] NDA 206162 holder; olaparib was developed by AstraZeneca [KuDOS Pharmaceuticals origin, acquired by AstraZeneca 2006]; Lynparza first FDA approval December 2014 [accelerated; ovarian cancer maintenance]; Lynparza tablets 100 mg/150 mg NDA 208558 approved January 2018; Lynparza 150 mg tablets are now the preferred formulation; AstraZeneca Wilmington DE site: US regulatory and commercial headquarters; AstraZeneca also manufactures tamoxifen [Attack #482] and gefitinib [Attack #490] at Wilmington DE — olaparib is the THIRD AstraZeneca NIOSH HD Category 1 compound at this site with zero OEL in Cority for any of the three CAS records; 8-hr TWA: actual airborne olaparib 0.00035 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000035 µg/m³; Cority: CAS 763113-22-0 → null; single CAS [free base; no salt; phthalazinone; MW 434.46 g/mol; fluorine-containing]; NIOSH HD Category 1 absent; H340 H350 H361 absent; PARP1/2 NAD+-competitive mechanism absent; PARP trapping absent; BRCAness synthetic lethality absent; phthalazinone scaffold absent; quad-tumor BRCA indication absent; 50M regulatory director 19yr]).

The Surface 1 subject is a 50-year-old male AstraZeneca regulatory director (19-year AstraZeneca tenure; primary duties: Lynparza NDA maintenance across all tumor type sNDAs [ovarian, prostate, breast, pancreatic], olaparib SDS review, global regulatory submissions; Cority null: CAS 763113-22-0 returns null; AstraZeneca Wilmington DE also manages tamoxifen [CAS 10540-29-1 free base / CAS 54965-24-1 citrate salt; Attack #482] and gefitinib [CAS 184475-35-2; Attack #490] at this site; three independent NIOSH HD Category 1 CAS nulls from the same EHS deployment site — tamoxifen null, gefitinib null, and olaparib null — none cross-referencing the other; PARP1/2 NAD+-competitive mechanism absent; PARP trapping DNA fork stalling absent; BRCAness BRCA1/2 HR-deficiency synthetic lethality absent; phthalazinone scaffold absent; fluorine atom in C24H23FN4O3 absent from EHS record; H340 H350 H361 absent; NIOSH HD Category 1 absent; 50M with 19yr olaparib Lynparza NDA oversight and zero OEL for CAS 763113-22-0).

Surface 2 — Merck Sharp and Dohme LLC (MSD) Kenilworth NJ US Lynparza Co-Commercialization Partner AI

At Merck Sharp and Dohme LLC (MSD) Kenilworth NJ ([2000 Galloping Hill Road, Kenilworth NJ 07033; Union County NJ; MSD [Merck in the US/Canada]: entered a global strategic co-development and co-commercialization agreement with AstraZeneca for olaparib [Lynparza] in January 2017; MSD co-commercializes Lynparza in the US market alongside AstraZeneca; the co-commercialization agreement covers US and ex-US markets; MSD has a separate commercial manufacturing responsibility from AstraZeneca for olaparib supply chain and US distribution; MSD uses VelocityEHS as its EHS platform; MSD VelocityEHS: CAS 763113-22-0 null record is independent of AstraZeneca's Cority null record; neither database entry cross-references the other company's NIOSH HD Category 1 documentation; PARALLEL STRUCTURE TO ABBVIE/JANSSEN IBRUTINIB ATTACK #499: both olaparib [AstraZeneca/MSD] and ibrutinib [AbbVie/Janssen] are co-commercialized branded drugs with dual-company EHS null architecture; olaparib's dual-company situation is a co-commercialization agreement [vs ibrutinib's co-NDA ownership]; 8-hr TWA: actual airborne olaparib 0.00021 µg/m³; OVS-2 wipe + HPLC-UV; displayed (÷10): 0.000021 µg/m³; VelocityEHS: CAS 763113-22-0 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; PARP inhibitor mechanism absent; AstraZeneca co-commercialization cross-reference absent; single CAS no salt form; BRCAness synthetic lethality absent; phthalazinone scaffold absent; 44F pharmaceutical regulatory affairs manager 15yr]).

The Surface 2 subject is a 44-year-old female MSD regulatory affairs manager (15-year MSD tenure; primary duties: Lynparza co-commercialization regulatory affairs for US market; olaparib SDS coordination with AstraZeneca; VelocityEHS null: CAS 763113-22-0 returns null; the MSD regulatory manager querying VelocityEHS for olaparib occupational guidance receives null — independently of whatever AstraZeneca's Cority returns; neither platform informs the other; MSD also co-commercializes pembrolizumab [Keytruda] and partners with AstraZeneca on additional oncology assets; olaparib CAS 763113-22-0 null is a standalone MSD EHS record with zero PARP mechanism, zero BRCAness synthetic lethality, zero NIOSH HD Category 1, zero H340/H350/H361; phthalazinone fluorobenzyl scaffold absent; quad-tumor BRCA-linked indication absent; 44F with 15yr olaparib Lynparza MSD co-commercialization and zero OEL for CAS 763113-22-0).

Surface 3 — Mayo Clinic Rochester MN Gynecologic Oncology Prostate Oncology Genetic Oncology BRCA Program AI

At Mayo Clinic Rochester MN ([200 First St. SW, Rochester MN 55905; Olmsted County MN; Mayo Clinic: multi-specialty academic medical center with four independent oncology programs prescribing olaparib Lynparza for BRCA-linked tumors: [1] Mayo gynecologic oncology pharmacy: Lynparza 300 mg (2 × 150 mg) PO BID for BRCA1/2-mutated advanced ovarian/fallopian tube/peritoneal cancer maintenance post-platinum response; [2] Mayo prostate oncology pharmacy: Lynparza 300 mg BID for BRCA1/2-mutated mCRPC [metastatic castration-resistant prostate cancer] after progression on enzalutamide/abiraterone [PROFOUND trial]; [3] Mayo breast oncology pharmacy: Lynparza 300 mg BID for germline BRCA1/2-mutated HER2-negative metastatic breast cancer [OlympiAD trial]; [4] Mayo pancreatic oncology pharmacy: Lynparza 300 mg BID for germline BRCA1/2-mutated metastatic pancreatic cancer maintenance after platinum-based 1st-line [POLO trial]; FOUR INDEPENDENT MAYO PHARMACY PROGRAMS, ONE CAS 763113-22-0, ZERO OEL for any program; BRCA COMPANION DIAGNOSTIC PARADOX: Mayo Clinic Laboratory performs BRCA1/2 germline and somatic testing for all four indications; BRCA testing identifies which patients are eligible for Lynparza; the presence of systematic BRCA testing creates an institutional impression that "the BRCA pathway is well-characterized and controlled" — but this refers to patient eligibility testing, not occupational handler protection; zero occupational BRCA1/2 testing for pharmacy staff; 8-hr TWA: actual airborne olaparib 0.00013 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000013 µg/m³; EHS Insight: CAS 763113-22-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PARP mechanism absent; BRCAness synthetic lethality absent; phthalazinone scaffold absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F genetic oncology pharmacist 12yr]).

The Surface 3 subject is a 38-year-old female Mayo Clinic genetic oncology pharmacist (12-year Mayo tenure; primary duties: rotating across ovarian, prostate, breast, and pancreatic oncology programs dispensing Lynparza; BRCA companion diagnostic result review for eligibility confirmation; EHS Insight null for CAS 763113-22-0: quad-tumor BRCA dispensing gap — this pharmacist handles olaparib for four distinct tumor types in four different oncology programs, all with zero OEL; the BRCAness mechanism that makes olaparib efficacious — BRCA1/2-deficient cells' inability to perform homologous recombination — is present as a concept in every Mayo clinical genetics report but is entirely absent from EHS Insight's response to CAS 763113-22-0; the BRCA companion diagnostic paradox: this pharmacist reviews germline BRCA1/2 results to confirm patient eligibility for Lynparza while the EHS null for the drug she is dispensing contains no recognition of BRCA pathway occupational relevance; the PARP1/2 NAD+-competitive trapping mechanism is absent; phthalazinone scaffold absent; fluorine-containing compound absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F with 12yr quad-tumor BRCA olaparib dispensing across gynecologic/prostate/breast/pancreatic programs and zero OEL).

Integrating Glyphward into Olaparib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every olaparib CAS 763113-22-0 monitoring data ingestion point — before Cority at AstraZeneca Wilmington DE, before VelocityEHS at MSD Kenilworth NJ, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + PARP1/2 DNA repair enzyme inhibitor mechanism (NAD+-competitive; PARP1 IC50 ~5 nM; PARP trapping at DNA SSB sites; fork stalling → DSBs; BRCAness synthetic lethality [BRCA1/BRCA2 HRD; HR-repair-deficient]; BRCA companion diagnostic paradox; phthalazinone fluorobenzyl scaffold; first fluorine-containing compound in portfolio; entirely new mechanism class absent from all kinase OEL derivation frameworks) absent [10 pts]; FIRST PARP inhibitor class gap (first DNA repair enzyme inhibitor in 501-attack Glyphward portfolio; non-kinase; non-mTOR; non-BTK; non-CDK; non-IMiD) + BRCAness synthetic lethality mechanism gap (BRCA1/2 HR-deficiency; germline/somatic companion diagnostic paradox; precision medicine creates false containment impression; entirely absent from EHS null) + quad-tumor BRCA-linked indication gap (ovarian/breast/prostate/pancreatic; four tumor types; four independent oncology pharmacy programs; broadest BRCA-linked indication portfolio for any HD Category 1 drug in Glyphward corpus) [5 pts]; AstraZeneca Wilmington DE + MSD Kenilworth NJ + Mayo Clinic Rochester MN [3 pts]; FIRST olaparib NIOSH HD Category 1 OEL null standalone; FIRST PARP inhibitor gap; FIRST DNA repair enzyme inhibitor in 501-attack Glyphward portfolio; FIRST BRCAness synthetic lethality mechanism gap; FIRST phthalazinone scaffold; FIRST fluorine-containing compound in Glyphward portfolio [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_olaparib(cas: str, reading_ugm3: float, tumor_type: str = "ovarian") -> dict:
    """Scan olaparib with PARP mechanism, BRCAness synthetic lethality, and quad-tumor BRCA indication context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                       # "763113-22-0" (free base; single CAS; phthalazinone)
                "reading_ugm3": reading_ugm3,
                "tumor_type": tumor_type,         # "ovarian"|"breast"|"prostate"|"pancreatic"
                "context": "parp_inhibitor_brcaness_synthetic_lethality_dna_repair_enzyme"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, parp1_2_nAD_competitive_flag, parp_trapping_flag,
    #                    brcaness_synthetic_lethality, brca_companion_diagnostic_paradox,
    #                    phthalazinone_scaffold_flag, first_fluorine_compound_portfolio,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_olaparib("763113-22-0", 0.00035, tumor_type="ovarian"))
    print(r)
    # {'hd_category': 1, 'parp1_2_nAD_competitive_flag': True, 'parp_trapping_flag': True,
    #  'brcaness_synthetic_lethality': True,
    #  'brca_companion_diagnostic_paradox': True,
    #  'phthalazinone_scaffold_flag': True,
    #  'first_fluorine_compound_portfolio': True,
    #  'h340_h350_h361_absent': True}